Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „occurring“
Suchtreffer
Begriffe & Kennungen
Blincyto · 4.8 · The observed time to onset of ICANS ranged from 0 to 299 days with the majority of ICANS occurring within the
Eintrag öffnenBonviva · 4.8 · 6 Table 1: Adverse reactions occurring in postmenopausal women receiving Bonviva 150 mg once monthly or ibandr
Eintrag öffnenBonviva · 4.8 · Table 1: Adverse reactions occurring in postmenopausal women receiving Bonviva 3 mg injection every 3 months o
Eintrag öffnenBrukinsa · 4.8 · 34 Zanubrutinib in combination with obinutuzumab The most commonly occurring adverse reactions (≥20%) of zanub
Eintrag öffnenBrukinsa · 4.8 · The most commonly occurring adverse reactions (≥20%) of zanubrutinib monotherapy were upper respiratory tract
Eintrag öffnenBrukinsa · 4.8 · The most commonly occurring adverse reactions (≥20%) of zanubrutinib monotherapy were upper respiratory tract
Eintrag öffnenBrukinsa · 4.8 · Zanubrutinib in combination with obinutuzumab The most commonly occurring adverse reactions (≥20%) of zanubrut
Eintrag öffnenCaelyx pegylated liposomal · 4.8 · Severe adverse reactions (Grade 3/4 adverse reactions occurring in ≥ 2% of patients) were neutropaenia, PPE, l
Eintrag öffnenCarvykti · 4.8 · Table 5 lists the incidences of Grade 3 or Grade 4 cytopenias occurring after dosing not resolved to Grade 2 o
Eintrag öffnenCelsentri · 4.8 · Delayed type hypersensitivity reactions, typically occurring within 2-6 weeks after start of therapy and inclu
Eintrag öffnenCelsentri · 4.8 · Delayed type hypersensitivity reactions, typically occurring within 2-6 weeks after start of therapy and inclu
Eintrag öffnenCelsentri · 4.8 · The most frequently reported adverse reactions occurring in the Phase 2b/3 studies were nausea, diarrhoea, fat
Eintrag öffnenCelsentri · 4.8 · The most frequently reported adverse reactions occurring in the Phase 2b/3 studies were nausea, diarrhoea, fat
Eintrag öffnenCholestagel · 4.8 · Summary of the safety profile The most frequently occurring adverse reactions are flatulence and constipation,
Eintrag öffnenColumvi · 4.8 · 15 Adverse reactions occurring in relapsed or refractory DLBCL patients treated with Columvi in combination wi
Eintrag öffnenColumvi · 4.8 · Adverse reactions occurring in relapsed or refractory DLBCL patients treated with Columvi monotherapy (n=145)
Eintrag öffnenConbriza · 4.8 · The majority of adverse reactions occurring during the clinical trials were mild to moderate in severity and d
Eintrag öffnenDarunavir Viatris (previously Darunavir Mylan) · 4.8 · Rash In clinical trials, rash was mostly mild to moderate, often occurring within the first four weeks of trea
Eintrag öffnenDarunavir Viatris (previously Darunavir Mylan) · 4.8 · Rash In clinical trials, rash was mostly mild to moderate, often occurring within the first four weeks of trea
Eintrag öffnenDocetaxel Accord · 4.8 · For combination with ADT and with prednisone or prednisolone (STAMPEDE study), adverse events occurring over t
Eintrag öffnen